Servier Gets Expanded FDA Approval of Tibsovo for IDH1-Mutated AML

May 27, 2022

The FDA has approved Servier Pharmaceuticals’ Tibsovo (ivosidenib) in combination with Bristol Myers Squibb’s Vidaza (IV formulation of azacitidine) to treat patients 75 years and older with newly diagnosed isocitrate dehydrogenase-1 (IDH1) mutation in acute myeloid leukemia (AML) or who have comorbidities that preclude use of intensive induction chemotherapy.

“People living with acute myeloid leukemia, especially those who are newly diagnosed and are not eligible for intensive chemotherapy, have had few treatment options,” said Susan Pandya, vice president of clinical development and head of cancer metabolism global development oncology & immuno-oncology at Servier.

Tibsovo, an IDH1 inhibitor, was first approved by the FDA in 2018. The expanded approval for IDH1-mutated AML joins the list of other approved indications, including relapsed or refractory AML and previously treated locally advanced or metastatic cholangiocarcinoma.

The expanded approval was based on a phase 3 study. Results showed that the Tibsovo and Vidaza treatment combination led to statistically significant improvements in event-free survival and overall survival.

View today's stories